Announcing the failure of the latest trial Tuesday, the two companies said they would halt development of Dimebon for all indications and cease an ongoing open-label extension study in Alzheimer's disease.
WSJ: Medivation, Pfizer Alzheimer's Drug Fails to Meet Study Goals